American College of Rheumatology 2025 guidelines for the treatment of systemic lupus erythematosus without renal involvement
https://doi.org/10.14412/19967012-2025-6-19-24
Abstract
The article presents the new 2025 guidelines of the American College of Rheumatology (ACR) for the treatment of systemic lupus erythematosus (SLE) without renal involvement, with commentary from leading SLE experts — staff members of the V.A. Nasonova Research Institute of Rheumatology.
Keywords
American College of Rheumatology guidelines,
systemic lupus erythematosus without renal involvement,
treatment
Supporting agencies: The article was prepared within the framework of the research project (state assignment № PK 122040400024-7). The investigation has not been sponsored
About the Authors
E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Aleksandrovna Aseeva
34A, Kashirskoe Shosse, Moscow 115522
S. K. Soloviev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. A. Pletnev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. V. Dacina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: history and modernity. Nauchno-prakticheskaya revmatologiya. 2022;60(4):397-412. (In Russ.).
2. https://rheumatology.org/lupus-guideline
3. Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-target SLE recommendations from the International Task Force and Russian experts’ commentaries. Nauchno-prakticheskaya revmatologiya. 2015;53(1):9-16. (In Russ.).
4. Piga M, Parodis I, Touma Z, et al. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force. Autoimmun Rev. 2025 Apr 30;24(5):103773. doi: 10.1016/j.autrev.2025.103773.
5. Franklyn K, Lau CS, Navarra SV, et al; Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis2015-207726.
6. Van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021 Nov; 8(1):e000538. doi: 10.1136/lupus-2021-000538.
7. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2; 83(1):15-29. doi: 10.1136/ard-2023-224762.
8. Niebel D, de Vos L, Fetter T, et al. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. Am J Clin Dermatol. 2023 Jul;24(4):521-540. doi: 10.1007/s40257-023-00774-8.
9. Dima A, Jurcut C, Chasset F, et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022 Feb 14;14: 1759720X211073001. doi: 10.1177/1759720 X211073001.
10. Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr Opin Rheumatol. 2016 Sep;28(5):453-9. doi: 10.1097/BOR.0000000000000308.
11. Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Nauchno-prakticheskaya revmatologiya. 2021;59(5):537-546. (In Russ.).
12. Aseeva EA, Soloviev SK, Mesnyankina AA, et al. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Nauchno-Prakticheskaya Revmatologiya. 2016;54(1):31-37. (In Russ.).
13. Reshetnyak TM, Aseeva EA, Shumilova AA, et al. Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(6):14-21. (In Russ.). doi: 10.14412/1996-7012-2023-6-14-21.
14. Reshetnyak TM, Aseeva EA, Shumilova AA, et al. Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6month study). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024; 18(2):16-24. (In Russ.). doi: 10.14412/1996-7012-2024-2-16-24.
15. Solov'ev SK, Aseeva EA. The place of plasmapheresis in the treatment of rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2007;(4):47-54. (In Russ.).
16. Aseeva EA, Pokrovsky NS, Soloviev SK, et al. The first clinical experience with selective DNA plasmasorption using the NucleoCapture Device in the treatment of systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(2): 75-80. (In Russ.). doi: 10.14412/1996-7012-2024-2-75-80.
17. Lee YH, Song GG. Mortality in patients with systemic lupus erythematosus: A metaanalysis of overall and cause-specific effects. Lupus. 2024 Aug;33(9):929-937. doi: 10.1177/09612033241257134.
Review
For citations:
Aseeva EA, Soloviev SK, Pletnev EA, Dacina AV. American College of Rheumatology 2025 guidelines for the treatment of systemic lupus erythematosus without renal involvement. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(6):19-24. (In Russ.) https://doi.org/10.14412/19967012-2025-6-19-24
Views:
51
Email this article 